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Abstract
Objective: Early and regular care and treatment for human immunodeficiency virus (HIV) infection are associated with viral
suppression, reductions in transmission risk and improved health outcomes for persons with HIV. We determined, on a
population level, the association of care visits with time from HIV diagnosis to viral suppression.
Methods: Using data from 19 areas reporting HIV-related tests to national HIV surveillance, we determined time from
diagnosis to viral suppression among 17,028 persons diagnosed with HIV during 2009, followed through December 2011,
using data reported through December 2012. Using Cox proportional hazards models, we assessed factors associated with
viral suppression, including linkage to care within 3 months of diagnosis, a goal set forth by the National HIV/AIDS Strategy,
and number of HIV care visits as determined by CD4 and viral load test results, while controlling for demographic, clinical,
and risk characteristics.
Results: Of 17,028 persons diagnosed with HIV during 2009 in the 19 areas, 76.6% were linked to care within 3 months of
diagnosis and 57.0% had a suppressed viral load during the observation period. Median time from diagnosis to viral
suppression was 19 months overall, and 8 months among persons with an initial CD4 count #350 cells/mL. During the first
12 months after diagnosis, persons linked to care within 3 months experienced shorter times to viral suppression (higher
rate of viral suppression per unit time, hazard ratio [HR] = 4.84 versus not linked within 3 months; 95% confidence interval
[CI] 4.27, 5.48). Persons with a higher number of time-updated care visits also experienced a shorter time to viral
suppression (HR= 1.51 per additional visit, 95% CI 1.49, 1.52).
Conclusions: Timely linkage to care and greater frequency of care visits were associated with faster time to viral suppression
with implications for individual health outcomes and for secondary prevention.
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Introduction
Suppression of human immunodeficiency virus (HIV) plasma
viral load reduces HIV-related morbidity and mortality and can
prevent onward transmission of HIV [1]. However, less than 30%
of persons living with HIV in the United States have a suppressed
viral load [2,3]. Viral suppression is the outcome of sequential
steps in the continuum of care, including diagnosis, linkage and
retention in HIV care, and antiretroviral treatment (ART)
prescription and adherence [2–4].
Of the more than 1.1 million people living with HIV in the
United States, an estimated 200,000 are not aware of their
infection and therefore do not receive the benefits of care and
treatment [5]. However, even among those diagnosed, an
estimated 1 in 5 are not promptly linked to care and less than
half are in regular HIV care [6,7]. Studies have shown that
persons who enter care soon after diagnosis and maintain regular
care initiate ART earlier, have better adherence to ART, and
have better health outcomes [8–11]. In addition, adherence to
clinic visits was associated with earlier viral suppression and lower
cumulative viral load burden [10]. However, these findings were
based on persons who had already been linked to HIV medical
care at selected clinics, and information is not available at the
population level on the association between early entry to HIV
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care after diagnosis or frequency of HIV care visits and the time to
viral suppression. Shortening the time from HIV diagnosis to care
entry and viral suppression has important implications for HIV
treatment and prevention as this would shorten the time
individuals could potentially transmit the virus. However, limited
evidence has demonstrated a benefit to health outcomes among
persons linked to care within 3 months of HIV diagnosis, a goal set
forth by the National HIV/AIDS Strategy and a quality indicator
in a recent Institute of Medicine Report [12,13].
Population-based HIV surveillance data can be used to
determine care visits among persons with HIV based on reports
of CD4 and viral load test results, and test results can be used to
determine viral load and time to viral suppression. We used data
from the National HIV Surveillance System to determine the
associations between entry to care and number of care visits with
time to viral suppression. We hypothesized that linkage to care
within 3 months of HIV diagnosis and greater frequency of care
visits would be significantly associated with faster time to viral
suppression.
Methods
HIV infection is reportable in all 50 states, the District of
Columbia, and six U.S. dependent areas. All cases are reported
from state and local health departments to the Centers for Disease
Control and Prevention (CDC) without identifying information.
Assessments and elimination of duplicate reports occur both on the
state and national level. However, not all areas have mandatory
reporting of all HIV-related laboratory tests, including all values of
CD4 cell counts or percentages and viral load tests. Using data
from 19 jurisdictions (California [Los Angeles County and San
Francisco only], Delaware, District of Columbia, Georgia, Hawaii,
Illinois, Indiana, Iowa, Louisiana, Michigan, Minnesota, Missouri,
Nebraska, New Hampshire, New York, North Dakota, South
Carolina, West Virginia, Wyoming) with mandatory laboratory
reporting of HIV-related tests and reporting of all tests to national
HIV surveillance, we assessed factors associated with viral
suppression in persons .12 years old who were diagnosed with
HIV during 2009. Persons were followed through December 2011
and data were reported to CDC through December 2012.
We assessed time to viral suppression (defined as #200 copies/
mL) after HIV diagnosis, with an observation period from
diagnosis through December 2011. Patients were followed until
the earliest of viral suppression, death or the administrative
censoring date of December 2011. Patients who died or did not
attain viral suppression before December 2011 were censored.
Using data on CD4 and viral load test results, we defined two care
indicators: 1) early linkage to care ($1 CD4 or viral load test result
within 3 months of diagnosis), a goal of the National HIV/AIDS
Strategy and a quality indicator defined by the Institute of
Medicine [12,13], and 2) the number of care visits within the
observation period (number of CD4 or viral load test results) but
before or at viral suppression. Two or more CD4 or viral load test
results collected in the same calendar month were considered as
one care visit. We assessed outcomes overall and adjusted for sex,
race/ethnicity (black or African American [hereafter referred to as
‘black’], Hispanic or Latino, white, multiple/other race), age,
transmission category (male-to-male sexual contact, injection drug
use, male-to-male sexual contact and injection drug use, hetero-
sexual contact, and other), and severity of disease at diagnosis
(CD4 count ,200 cells/mL or opportunistic illness; CD4 count
200–350 cells/mL; CD4 count .350 cells/mL; and unknown,
based on reported CD4 test results or opportunistic illnesses within
3 months of diagnosis [for 0.7% of persons only CD4 percentage
was available and we assigned count equivalents as follows: CD4
percent ,14% as CD4 count of ,200 cells/mL, CD4 percent
14%–24% as CD4 count of 200–350 cells/mL, and CD4 percent
.24% as CD4 count of .350 cells/mL]) [14,15].
Statistical Analysis
Kaplan-Meier analyses were used to generate survival curves
and to estimate the median time to viral suppression overall and by
entry to care within 3 months and CD4 count at baseline. We used
Cox proportional hazards models to assess factors associated with
time to first suppressed viral load. Because entry to care and
subsequent care visits are on the causal pathway from HIV
diagnosis to viral suppression, two separate Cox models were
constructed with one model evaluating care entry within 3 months
and the other the time-updated cumulative number of care visits.
Adjusted models controlled for covariates listed above. The
proportionality of hazard assumption was tested for all covariates
included in the Cox models. Since there was a significant
interaction between linkage to care within 3 months of diagnosis
and time to viral suppression (i.e., non-proportional hazards), we
added a time interaction term and assessed the effect of linkage to
care on two time intervals (#12 months, and .12 months). For
the entry to care variable the proportional hazards assumption was
met for the .12 months time period. However, the proportional
hazards assumption was not met for the #12 months time period.
After examination of the plot of the kernel-smoothed hazard
functions it was clear that although not proportional, the hazard
rate for those who entered care within 3 months was consistently
higher than the rate for those that did not enter care within 3
months and thus it would be reasonable to report what is
essentially the average hazard ratio over this time period. Because
they accumulate over time, the number of care visits was handled
as a time-updated covariate in the models. Because the prevailing
treatment guidelines during the study period (2009) recommended
ART initiation at a CD4 count #350 cells/mL, we conducted
sensitivity analyses limited to participants with an initial CD4
count below this threshold. All analyses were performed using SAS
version 9.3 (SAS Institute Inc., Cary, NC), with statistical
significance defined as a 2-sided p-value,0.05.
Of the persons .12 years old and diagnosed in 2009 in the 19
jurisdictions, 141 (0.82%) were excluded from the analysis because
the date of diagnosis was incomplete (missing month of diagnosis).
For the 17,028 persons diagnosed with HIV included in the
analyses, information for transmission category was not available
for 5,648; these were retained in the analyses in the ‘‘Other’’
category. About 0.4% (1,175 of a total of 277,580 CD4 or viral
load tests) of CD4 or viral load tests were excluded because their
month difference could not be determined between the diagnosis
date and the specimen collection date (month of specimen
collection date is missing), and 0.04% (38 of a total of 103,361
viral load test results) of viral load test results were not valid and
were not included when calculating time to viral suppression.
Results
Of 17,028 persons diagnosed with HIV during the calendar
year 2009 and followed through December 2011 in the 19
jurisdictions, 51.4% were black, 19.0% were Hispanic or Latino,
24.8% were white and 4.7% were of other races (Table 1). The
majority were male (77.5%) and 47.3% had infection attributed to
male-to-male sexual contact. Nearly a third (29.4%) had a baseline
CD4 count of ,200 cells/mL or an AIDS diagnosis based on
opportunistic illness.
HIV Care Visits and Viral Suppression
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About three quarters of persons diagnosed with HIV (76.6%)
were linked to care within 3 months of diagnosis. Of the total of
17,028 persons, 1,828 had no evidence of care during the
observation period. For persons who entered care within the
observation period, the mean time from diagnosis to care entry
was 6 months (Kaplan-Meier estimate), and one month for those
who entered care within 3 months and 22 months for those who
entered care later.
Overall, 85.4% of persons diagnosed with HIV in 2009 had a
viral load test result within the observation period; 57.0% had a
suppressed viral load (Table 1). The percentage with viral
suppression during the observation period was higher among
persons with a lower baseline CD4 count compared to persons
with a higher CD4 or unknown CD4 count (e.g., 70.4% among
persons with stage 3 disease at baseline compared with 57.6%
among persons with CD4 count .350 cells/mL). The median
time from diagnosis to viral suppression was 19 months
(Kaplan-Meier estimate), and time to viral suppression was
shorter for those with entry to care within 3 months of
diagnosis compared with entry after 3 months of diagnosis
(Figure 1), with a median time of 12 months for persons with
entry within 3 months of diagnosis. Time to viral suppression
Table 1. Characteristics of adolescents and adultsa diagnosed with HIV infection, 2009, 19 U.S. jurisdictions.
Totalb Had a VL testc Had a suppressed VL testd
Characteristic No. (%) No.
% from the
overall
population No.
% from the
overall
population
% from the
persons with a VL
test
Sex
Male 13,201 (77.5%) 11,266 85.3 7,495 56.8 66.5
Female 3,827 (22.5%) 3,278 85.7 2,209 57.7 67.4
Age at diagnosis (yrs) 36.4612.3
13–24 3,484 (20.5%) 2,973 85.3 1,700 48.8 57.2
25–34 4,697 (27.6%) 4,042 86.1 2,671 56.9 66.1
35–44 4,325 (25.4%) 3,697 85.5 2,627 60.7 71.1
45–54 3,161 (18.6%) 2,692 85.2 1,908 60.4 70.9
55+ 1,361 (8.0%) 1,140 83.8 798 58.6 70
Race/ethnicity
Black/African American 8,757 (51.4%) 7,254 82.8 4,469 51 61.6
Hispanic/Latino 3,236 (19.0%) 2,748 84.9 1,937 59.9 70.5
White 4,228 (24.8%) 3,832 90.6 2,792 66 72.9
Other 807 (4.7%) 710 88 506 62.7 71.3
Transmission category
Male-to-male sexual contact 8,062 (47.3%) 7,129 88.4 4,839 60 67.9
Injection drug use 751 (4.4%) 634 84.4 403 53.7 63.6
Male-to-male sexual contact and
injection drug use
392 (2.3%) 356 90.8 231 58.9 64.9
Heterosexual contact 2,174 (12.8%) 1,959 90.1 1,322 60.8 67.5
Othere 5,649 (33.2%) 4,466 79.1 2,909 51.5 65.1
Baseline CD4 countf
,200 cells/mL or Stage 3, AIDS 5,009 (29.4%) 4,663 93.1 3,524 70.4 75.6
200–350 cells/mL 2,052 (12.1%) 1,986 96.8 1,520 74.1 76.5
.350 cells/mL 5,118 (30.1%) 4,949 96.7 2,949 57.6 59.6
Unknown 4,849 (28.5%) 2,946 60.8 1,711 35.3 58.1
Care entry within 3 months
of diagnosis
No 3,984 (23.4%) 2,039 51.2 1,176 29.5 57.7
Yes 13,044 (76.6%) 12,505 95.9 8,528 65.4 68.2
Total 17,028 (100%) 14,544 85.4 9,704 57 66.7
a17028 adolescents and adults (aged .12 years) diagnosed in 2009, with followed up through December 31, 2011.
bPercentage reflects the column percentage; numerator is the number of persons in the group and denominator is the total number of persons diagnosed with HIV in
2009. Mean (standard deviation) was also calculated for age at HIV diagnosis.
cHad a viral load (VL) test within follow-up period. Percentage reflects number of persons with a VL test among the total population.
dHad a suppressed VL within follow-up period. For percentage among total population, the denominator is the total population (number of persons diagnosed with HIV
in that group). For the percentage among persons with VL test, the denominator is the number of persons with a VL test in that group.
eIncludes 5,648 persons with unknown transmission category.
fCD4 test result or opportunistic illnesses within 3 months of diagnosis; persons without a CD4 test result or OI within 3 months of diagnosis are classified as ‘‘unknown’’.
doi:10.1371/journal.pone.0084318.t001
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was also shorter for persons with a lower CD4 count at baseline
(Figure 2), with a median of 8 months for persons with CD4
count #350 cells/mL at baseline (Kaplan-Meier estimate)
compared with the 19 months in the overall sample. During
the first 12 months after diagnosis, persons linked to care within
3 months experienced shorter times to viral suppression (hazard
ratio [HR]= 4.84 compared to those not linked to care within 3
months of diagnosis; 95% confidence interval [CI] 4.27, 5.48)
(Table 2). Linkage to care within 3 months of diagnosis had an
attenuated effect on the time to viral suppression in the time
period 12 months after diagnosis (HR=1.45, 95% CI 1.29,
1.62). Persons with a higher number of time-updated care visits
also experienced a shorter time to viral suppression (HR=1.51
per additional visit, 95% CI 1.49, 1.52) (Table 2).
Other factors associated with shorter time to viral suppression,
based on the entry to care model, included sex (female versus male
HR=1.25, 95% CI 1.18, 1.33), older age (HR=1.09 per 10 years,
95% CI 1.07, 1.11), and more advanced disease at diagnosis (lower
CD4 count; for example, HR=1.77 for persons with CD4 count
,200 cells/mL or opportunistic illness versus persons with CD4
count .350 cells/mL; 95% CI 1.68, 1.86). Time to viral
suppression was longer among blacks compared with whites
(HR=0.72, 95% CI 0.69, 0.76).
In a sensitivity analysis excluding the 1,885 (11.1%) of persons
with suppressed viral load or censored (dead) in less than 3 months
from diagnosis and using data for the remaining 15,143 persons,
the HR was attenuated but provided the same conclusion for entry
to care (adjusted HR=3.47, 95% CI 3.04, 3.96 for early time
period [3–12 months]). The adjusted HR was similar for the
number of care visits (HR=1.49, 95% CI 1.47, 1.50).
Discussion
Using population-based data from the National HIV Surveil-
lance System, study findings provide the first empirical evidence to
validate that linkage to care within 3 months of diagnosis is
significantly associated with more timely viral suppression,
providing validation for the linkage goal of the National HIV/
AIDS Strategy and the related Institute of Medicine core indicator
[12,13]. The focus for public health should be on early clinical
care; however, most studies focus on viral suppression only after
care entry, such as many prior publications on the continuum of
care [2–4]. The time from diagnosis to viral suppression is a novel
metric that surveillance can capture, spanning the anchoring
points on both ends of the HIV care continuum. While similar
findings from an earlier study were based on a clinic population
that, per definition, was in care [10], these new findings support
that, on a population level, prompt linkage improves outcomes
with implications for population health and secondary prevention
including treatment as prevention approaches. As new testing
technologies can diagnose HIV at earlier stages, when persons
may be more infectious and may continue to engage in risk
behavior, prompt linkage and viral suppression may have an even
larger impact on reducing HIV transmission in the future. While
coordination of care across agencies and jurisdictions has varied
historically, shortening the time of entry to care will require
integration of testing, prevention and treatment services across
public health departments, community-based organizations, and
medical clinics.
Beyond timely linkage to care, better early retention in care, as
measured by the cumulative number of care visits following
diagnosis, was also associated with faster time to viral suppression.
This likely reflects more expeditious initiation of ART among
Figure 1. Kaplan-Meier survival curve for time from HIV diagnosis to viral suppression, by entry to care within 3 months of HIV
diagnosis.
doi:10.1371/journal.pone.0084318.g001
HIV Care Visits and Viral Suppression
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e84318
persons seen more often. As treatment guidelines now recommend
ART initiation at any CD4 count [16,17], our findings suggest the
importance of timely care entry and early retention will become
even more important going forward. While the time to viral
suppression for the overall population was 19 months, among
those with an initial CD4 count #350 cells/mL, in whom ART
initiation was clearly recommended by treatment guidelines
during the study period (2009), the median time to suppression
was only 8 months. In the future, it is anticipated that ART will be
started earlier for all newly diagnosed patients, regardless of CD4
count, such that the notable gap observed in time to viral
suppression according to CD4 count is expected to diminish
considerably. More timely viral suppression should become
achievable for all patients, with care entry within 3 months of
diagnosis and more frequent attendance at HIV care visits playing
a prominent role in achieving this goal.
In addition, our analyses revealed disparities in time to viral
suppression by sex, age, race/ethnicity, and transmission category,
another major focus of the National HIV/AIDS Strategy.
Ensuring that people receive care and treatment is critical to
increase the proportion of HIV-infected individuals who achieve a
suppressed viral load and to realize the benefits of treatment to
reduce HIV transmission in the United States. Improvements are
also needed to address disparities in care and treatment.
Overall, a high proportion of persons diagnosed with HIV are
linked to care within 3 months, similar to earlier findings based on
HIV surveillance and a meta-analysis of published reports [7,18],
and the majority had a suppressed viral load within the
observation period. Viral suppression among the newly diagnosed
persons included in the analyses was higher than the estimated
percentage with viral suppression previously reported for the entire
U.S. population of persons living with diagnosed HIV (30.5%–
34.9% [2,3]), but our results were similar to viral suppression
reported for persons in care (62%–73% [2,19]). This may reflect
earlier findings indicating that persons who are more recently
diagnosed or who have been in care for a shorter period of time
are more likely to be in continuous care [6,20]. Lack of viral
suppression or difference in time to viral suppression among
subgroups may be due to delayed prescription or adherence to
ART or barriers to accessing care. A limitation of surveillance data
is the lack of information regarding ART utilization and
adherence, such that the role of these steps on the HIV care
continuum could not be evaluated. However, surveillance is
unique in the capture of both dates of HIV diagnosis as well as
viral load measures allowing measurement of the time interval
between these two points on either end of the continuum. We
suggest this time interval may serve as a novel, valuable indicator
for longitudinal monitoring using population-based HIV surveil-
lance data at a jurisdiction, state and national level.
Study results reflect the prioritization of treatment for persons
with more advanced disease, with shorter times to viral
suppression for those with advanced disease compared with
persons with CD4 counts .350 cells/mL at diagnosis. Indeed, in
sensitivity analyses restricted to participants with initial CD4
counts #350 cells/mL the median time to viral suppression was
less than half the time observed for the overall sample (8 vs. 19
months by Kaplan-Meier estimate). Treatment guidelines at the
time recommended ART prescription based on stage of disease
and other relevant factors [21,22]. Because guidelines now
recommend universal offering of treatment, it is anticipated that
timely care entry and regular visit frequency will become even
more paramount to ART uptake and success [16,17].
Our results are similar to earlier findings, conducted among
persons who had entered HIV medical care, among whom a lower
Figure 2. Kaplan-Meier survival curve for time from HIV diagnosis to viral suppression, by baseline CD4 count.
doi:10.1371/journal.pone.0084318.g002
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percentage of viral suppression was observed in blacks compared
with whites and among persons with HIV infection attributed to
transmission other than male-to-male sexual contact [2,7]. Factors
that may contribute to reduced access to care and treatment
include lack of social support, competing child care responsibilities,
food insecurity, unstable housing, lack of transportation, lower
education, poverty, unemployment, homelessness, and mental
health or substance abuse problems [23,24]. In addition,
differences exist in health insurance coverage, with 32% of
Latinos, 21% of blacks, and 16% of whites being uninsured [25].
Clearly, improvements are needed to achieve national goals of
alleviating disparities in HIV care and outcomes, with these
population-based data from newly diagnosed persons corroborat-
ing clinic-based data among those in care.
Our analysis was subject to several limitations. Data were
available from a limited number of areas; the 19 jurisdictions
represent 37.5% of all diagnoses in 2009 in the United States.
However, the demographic characteristics were similar among the
persons included in the analyses compared to the overall
population diagnosed with HIV in the United States in 2009. As
additional areas improve laboratory reporting to CDC, future
estimates of care utilization will be more representative. Informa-
tion was also not available to determine whether CD4 or viral load
tests were ordered by emergency departments or inpatient settings,
and people with HIV may have CD4 or viral load tests performed
but fail to attend the outpatient visit. However, surveillance data
provide information on care measures that are not subject to
limitations of patient recall or appointment tracking and measures
can be consistently applied to all locations. Numbers were too
small to report HRs for other individual race groups. For persons
who move to another jurisdiction after HIV diagnosis, surveillance
protocols call for reporting of information from both jurisdictions
Table 2. Factors associated with viral suppressiona among adolescents and adults diagnosed with HIV infectionb, 2009, 19 U.S.
jurisdictions.
Adjusted Cox proportional hazard model,
entry to care
Adjusted Cox proportional hazard mode,
number of care visits
Characteristic Hazard ratioc (95% CI) P-value Hazard ratioc (95% CI) P-value
Sex
Female 1.25 (1.18 to 1.33) ,.0001 1.27 (1.20 to 1.35) ,.0001
Male Reference Reference
Age at diagnosis (per 10 years) 1.09 (1.07 to 1.11) ,.0001 1.08 (1.06 to 1.10) ,.0001
Race/ethnicity
Black/African American 0.72 (0.69 to 0.76) ,.0001 0.74 (0.70 to 0.78) ,.0001
Hispanic/Latino 0.91 (0.86 to 0.97) 0.0032 0.87 (0.82 to 0.92) ,.0001
Other 1.00 (0.91 to 1.10) 0.9495 0.94 (0.85 to 1.03) 0.1874
White Reference Reference
Transmission category
Injection drug use 0.78 (0.70 to 0.87) ,.0001 0.66 (0.59 to 0.74) ,.0001
Male-to-male sexual contact and
injection drug use
0.87 (0.76 to 0.99) 0.0394 0.86 (0.75 to 0.98) 0.0232
Heterosexual contact 0.87 (0.81 to 0.94) 0.0004 0.86 (0.80 to 0.92) ,.0001
Otherd 0.80 (0.76 to 0.85) ,.0001 0.83 (0.78 to 0.87) ,.0001
Male-to-male sexual contact Reference Reference
Baseline CD4 counte
,200 cells/mL or Stage 3, AIDS 1.77 (1.68 to 1.86) ,.0001 1.57 (1.49 to 1.66) ,.0001
200–350 cells/mL 1.66 (1.56 to 1.76) ,.0001 1.65 (1.55 to 1.75) ,.0001
Unknown 1.10 (1.01 to 1.20) 0.0323 1.21 (1.13 to 1.29) ,.0001
.350 cells/mL Reference Reference
Care entry within 3 months of diagnosisf
Early time period (0–12 months) 4.84 (4.27 to 5.48) ,.0001
Later time period (13–35 months) 1.45 (1.29 to 1.62) ,0.0001
The cumulative number of care
visits after diagnosisg
1.51 (1.49 to 1.52) ,.0001
aViral suppression defined as ,=200 copies/ml.
b17,028 adolescents and adults (aged .12 years) diagnosed in 2009, with followed up through December 31, 2011; 7, 324 censored (43.01%).
cA hazard ratio .1 indicates a higher rate of viral suppression per unit time among the group of interest (e.g., those with early care entry vs. those who did not). Hazard
ratio is adjusted for all other covariates in the table.
dIncludes 5,648 persons with unknown transmission category.
eCD4 test result or opportunistic illnesses within 3 months of diagnosis; persons without a CD4 test result or OI within 3 months of diagnosis are classified as
‘‘unknown’’.
fDefined as $1 CD4 or VL test result within 3 months of diagnosis.
gThe number of care visits is a time-updated covariate in the model because it accumulates over time. Hazard ratio per additional visit.
doi:10.1371/journal.pone.0084318.t002
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including, at minimum, the first CD4 count (any value and the first
CD4 count ,200 cells/mL at any time) and viral load test results
after first diagnosis in the jurisdiction. Persons are de-duplicated in
the national surveillance database while maintaining information
reported from all jurisdictions. The percentage of persons who
moved during the follow-up time is expected to be small; however,
for persons with unsuppressed viral load who moved to another
jurisdiction where viral suppression was achieved it is possible that
information was not reported to CDC. This could result in an
underestimation of the effect if care was accessed early.
In summary, the results support strengthening efforts to improve
engagement in care among persons newly diagnosed with HIV,
validating the importance of the Institute of Medicine core
indicator of linkage to care within 3 months. Effective interven-
tions need to assure not only prompt linkage but also that
subsequent retention in care is established after the first visit [26].
A review of interventions has shown that strategies exist that can
improve retention in care [27]. Such strategies include case
management building on patients’ strengths, peer navigation,
reducing structural- and system-level barriers, and effective
communication between patients and providers [27–32]. Success-
ful implementation of such strategies is imperative to achieving the
goals of the National HIV/AIDS Strategy, and to maximizing
domestic HIV treatment and prevention success.
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